Contributions
Abstract: PB2093
Type: Publication Only
Background
Most patients with intermediate-2 and high-risk myelodysplastic syndrome (MDS) have a median age of 75 years and 25% of them are diagnosed beyond 80 years of age. Therefore, many of them may have great difficulty to travel to the hospital during the 7 days of duration of each cycle of 5-azacytidine treatment.
Aims
To analyse the health impact of the administration of 5-azacytidine in the domiciliary care and to evaluate the therapeutic adherence.
Methods
2-year prospective observational study on 20 MDS patients with a median of age of 75 years, with difficulty to travel to the day hospital to received treatment with 5-azacytidine during 7 days. The drug was prepared in the hospital pharmacy service, using the water reconstitution method for refrigerated injections and kept in refrigerator (2-8 ºC), resulting in both chemically and physically stable solutions for 22 hours. Once the inclusion of the patient in the study was confirmed by the haematologist, the prescribed treatment regime was informed to the pharmacy service and to the nurse to organize medication regime in the domiciliary care. The variables considered in this study were: beginning of treatment with 5-azacytidine, treatment duration, level of satisfaction of patients, treatment adherence and detected side effects.
Results
20 MDS patients received treatment with 5-azacytidine in domiciliary care during a mean of 15 months of treatment. 70% of the patients showed great difficulty to travel to the day hospital because they required an accompanying person and 30% did not possess supporting infrastructure. 100 % of the patients were highly satisfied with the service, therapeutic adherence improved in 95% and it was detected side effects in 15% of them (neutropenia, anaemia and gastrointestinal reactions).
Conclusion
The administration of 5-azacytidine in domiciliary care in MDS older patients with difficulty to travel to the day hospital has allowed to bring support to these patients, improving the day hospital logistics, increasing the satisfaction of the patients and its adherence to the treatment and offering a better quality healthcare.
Session topic: 10. Myelodysplastic syndromes – Clinical
Keyword(s): Health care, Myelodysplasia, Treatment
Abstract: PB2093
Type: Publication Only
Background
Most patients with intermediate-2 and high-risk myelodysplastic syndrome (MDS) have a median age of 75 years and 25% of them are diagnosed beyond 80 years of age. Therefore, many of them may have great difficulty to travel to the hospital during the 7 days of duration of each cycle of 5-azacytidine treatment.
Aims
To analyse the health impact of the administration of 5-azacytidine in the domiciliary care and to evaluate the therapeutic adherence.
Methods
2-year prospective observational study on 20 MDS patients with a median of age of 75 years, with difficulty to travel to the day hospital to received treatment with 5-azacytidine during 7 days. The drug was prepared in the hospital pharmacy service, using the water reconstitution method for refrigerated injections and kept in refrigerator (2-8 ºC), resulting in both chemically and physically stable solutions for 22 hours. Once the inclusion of the patient in the study was confirmed by the haematologist, the prescribed treatment regime was informed to the pharmacy service and to the nurse to organize medication regime in the domiciliary care. The variables considered in this study were: beginning of treatment with 5-azacytidine, treatment duration, level of satisfaction of patients, treatment adherence and detected side effects.
Results
20 MDS patients received treatment with 5-azacytidine in domiciliary care during a mean of 15 months of treatment. 70% of the patients showed great difficulty to travel to the day hospital because they required an accompanying person and 30% did not possess supporting infrastructure. 100 % of the patients were highly satisfied with the service, therapeutic adherence improved in 95% and it was detected side effects in 15% of them (neutropenia, anaemia and gastrointestinal reactions).
Conclusion
The administration of 5-azacytidine in domiciliary care in MDS older patients with difficulty to travel to the day hospital has allowed to bring support to these patients, improving the day hospital logistics, increasing the satisfaction of the patients and its adherence to the treatment and offering a better quality healthcare.
Session topic: 10. Myelodysplastic syndromes – Clinical
Keyword(s): Health care, Myelodysplasia, Treatment